FDA Collaborations With Industry Should Weigh Potential Conflicts Of Interest
Executive Summary
FDA recommends that agency staff avoid partnering with industry or trade associations unless the benefit outweighs any potential conflicts of interest raised by such leveraging arrangements
You may also be interested in...
Rx Risk Descriptions Need To Be Standardized, FDA’s Galson Tells CERTs
The standardization of risk expressions to compare drugs would be a desirable risk management tool, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, suggested at a recent CERTs meeting
Antimicrobial Placebo-Control Trial Should Be Required By FDA – PhRMA
Antimicrobial drug sponsors would be willing to conduct placebo-controlled trials in acute exacerbation of chronic bronchitis if FDA required such studies, Bristol-Myers Squibb VP-Infectious Disease & Clinical Development Roger Echols, MD, said
PhRMA/FDA Hepatox Group Wants Research On Liver Monitoring
Actelion's pulmonary hypertension agent Tracleer may provide an opportunity for FDA and industry to test new approaches for management of liver toxicity